DEA investigating Cerebral as $4.8 billion mental-health startup faces increasing scrutiny
- The US Drug Enforcement Administration is investigating $4.8 billion mental-health startup Cerebral.
- Cerebral is one of the few companies that prescribes highly regulated drugs like Adderall online without in-person visits.
- Cerebral said it was unaware of the interview and that it complied with the rules.
US Drug Enforcement Administration agents interview former Cerebral employees about mental-health startup , One of the few telehealth companies that prescribes controlled substances online , According to two people with direct knowledge of the matter.
The sources spoke on condition of anonymity because they understand an investigation is underway. The insider knows his identity.
Assistant Special Agent Michael Serio, in charge of the DEA’s Buffalo District Office, told Insider that the DEA could neither confirm nor deny the investigation.
“However, as the DEA we are concerned with the health and safety of the public,” Cereo said. “And any medical professional or organization that is prescribing drugs, we’re going to be monitoring their behavior.”
Insider, without naming the company, relayed information about the DEA’s interviews to Ronald Chapman II, a federal criminal defense attorney specializing in DEA investigations at Chapman Law Group, and Larry Cote, a former DEA attorney who now works at DEA Compliance with Health Services. Advise companies. , He said the nature of the agents’ questions and the fact that they interviewed former employees strongly suggest that an investigation is underway. Chapman said the investigation had traces of criminal investigation.
In those cases, the DEA typically interviews former employees first to avoid tipping business owners, and these interviews are meant to gather enough information to obtain a search warrant, Chapman said.
“They’re definitely investigating,” Chapman said. “The only question is whether this will change anything.”
Cote said that based on information provided by Insider, the DEA’s investigation could result in criminal, civil or administrative sanctions.
In a statement to Insider, Cerebral said the company was unaware of any DEA interviews and could not comment on what any of the interviewers might have said. Cerebral also said he was unaware of DEA investigations into Cerebral or his medical group. It said the DEA performs a number of important functions, including regulatory oversight. The company stated that the mental-health services provided through its platform comply with applicable federal and state laws and regulations and accepted medical practices.
The DEA interviews follow pushback against Cerebral by DEA offices in several states. Notably, according to an internal company document obtained by Insider, they have rejected some cerebral physicians’ applications for DEA licenses since at least last fall. DEA licenses are required to prescribe controlled substances.
The $4.8 billion company, backed by venture-capital firms including Cerebral, SoftBank and Oak HC/FT, provides medicine and therapy online to people with anxiety, depression, ADHD and other conditions. It’s one of a handful of online companies that prescribe strictly DEA-regulated substances, like Adderall and Xanax, that have the potential to be addictive.
The startup, which has served more than 200,000 patients since its 2020 launch, has faced scrutiny in recent months from news outlets, industry observers, and at least one former executive over its prescribing practices. was filed in the suit.
Major pharmacy chains, including Walmart and CVS, have blocked or delayed telehealth prescriptions for Adderall and other controlled substances. In some cases pharmacies have expressed concern that physicians at Cerebral and another company are writing too many prescriptions for the stimulant, The Wall Street Journal reported in April. Cerebral’s favorite pharmacy TruPill also recently suspended Adderall prescriptions, The Journal reported.
Cerebral said pharmacies may keep prescriptions for administrative reasons, such as problems with insurance coverage. The company works with them to answer any questions and resolve delays.
On Wednesday, The Journal reported that Cerebral will stop prescribing controlled substances such as Adderall to treat new patients with ADHD starting next week. Cerebral CEO Kyle Robertson confirmed the changes in an online letter.
Investigators’ questions suggest a comprehensive investigation
According to two sources with direct knowledge, DEA agents have interviewed former employees as recently as April. His questions were broad.
Sources said the agents asked about the rules of the cerebral set for prescribing controlled substances to patients. A source said the agents asked for banking information related to cerebral.
One of the sources said the DEA has also asked about Cerebral’s procedures for monitoring whether its physicians’ licenses are up to date and not on the federal list, barring them from participating in federal health programs.
In its statement, Cerebral said it has processes in place to verify physician licenses and check federal exclusion lists.
DEA agents are also investigating alleged incidents in which patients created more than one account with Cerebral, that source said.
Matt Trube, the former vice president in charge of product and engineering at Cerebral, sued the company, claiming they had been unfairly terminated. In the complaint, filed against the company on Wednesday, it alleged that it uncovered nearly 2,000 duplicate shipping addresses in Cerebral’s patient database in August 2021, suggesting that patients were trying to get more medicine, according to the complaint. Were able to set up accounts.
According to the complaint, a customer received duplicate prescriptions from multiple cerebral practitioners that suggested fraudulent prescriptions.
Trube and his attorney did not respond to a request for comment.
In its statement, Cerebral said that the safe medical care of patients is its top priority and it is continuously refining its internal processes to identify duplicate accounts.
The company said they verify patients’ identities when they sign up and during initial visits with physicians, and check the validity of shipping addresses. Accounts flagged as possible duplicates are removed, it said.
“Any attempt to obtain more medication than is prescribed is a significant issue for all health providers, including online healthcare providers,” Cerebral said in the statement.
Two lawyers said that the inquiry by the former employees by the DEA indicates that an investigation is underway
The lawyers, Chapman and Cote, said the DEA is interested in prescribing controlled substances, including the stimulant Adderall, used to treat ADHD.
Cerebral has faced scrutiny from news outlets and former employees for making it easier for patients to obtain controlled substances after a 30-minute online video session. Bloomberg’s Businessweek and The Journal reported that former physicians have said they felt pressure to prescribe controlled substances.
In the statement, Cerebral said physicians assess and treat patients based on their professional judgment. In addition to the initial appointment, they can schedule follow-up appointments, the company said.
“The availability of audio-visual appointments allows people to receive the care they need they otherwise would not be able to receive,” Cerebral said.
Chapman said the DEA may be concerned about whether cerebral providers are correlating with patients before prescribing controlled substances. This is often an issue in telemedicine, he said. The agency may also be interested in the relationship between Cerebral and the pharmacy it uses to fulfill prescriptions for controlled substances, he said.
“The DEA would more likely like a patient to go to the doctor in their home state, get an evaluation, get the medicine, fill it in at the local pharmacy,” Chapman said. “This widespread practice of telemedicine — the DEA just isn’t ready for it.”
The DEA conducts regular inspections and audits, as well as criminal investigations. Coates told Insider in an interview that the DEA would typically reach out to a company directly if it was performing a standard inspection or audit.
“I feel like it’s going to be more than a routine,” Cote said.
Chapman said questions from DEA agents about banking information also suggest a criminal investigation. This is because the DEA is looking for that information so that they can confiscate the accounts if necessary, he said.
Cerebral has seen DEA pushback in the past, insider learns
Cerebral has previously dealt with pushback from the DEA over the licensing of its physicians several months ago.
According to an internal company document seen by Insider, DEA offices in various states have rejected applications from cerebral physicians for DEA licenses.
Cerebral sets up WeWork addresses and instructs physicians to use them on their DEA license applications. According to sources close to the document and the DEA interview, DEA offices in states including North Carolina, Michigan and Illinois have rejected that view.
Chapman said that using a WeWork address would not be in line with the DEA’s requirement that a license be tied to an address where the providers actually practice. The agency requires that providers tell the agency they are practicing medicine, so agents can be there when they need to audit compliance, he said.
Cerebral said the addresses included by physicians on state-specific registration meet federal requirements. The company said in the statement that sometimes this includes the use of leased spaces under the control of Cerebral. The company said that only physicians with valid state DEA certification can prescribe controlled substances on Cerebral’s platform.
Do you have any tips about Cerebral that you want to share? Contact Blake Dodge (+1 ) and Shelby Livingston (+1 ) using the encrypted app Signal.
